However, this might not apply to myeloid cell populations, in which elevation of PD-L1 correlate with efficacy of PD-L1 blockade with atezolizumab in NSCLC patients with PD-L1-negative tumors [19]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.